Table 1.
Antifungal susceptibility testing and FKS1 gene sequencing for all C. albicans isolated.
| Isolate | Day | MIC (mg/L) for Antifungal Agents | MIC Strip (mg/L) | FKS Hotspot Mutations | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMB | AND | CAS | MFG | FCT | ITC | VRC | POS | FLZ | ISA | FKS1 HS1 | FKS1 HS2 | ||
| C. albicans | 8 | 0.5 | 0.015 | 0.03 | 0.008 | <0.06 | 0.06 | <0.008 | 0.03 | 0.25 | 0.5 | Wild type | Wild type |
| C. albicans | 33 | 0.5 | 0.015 | 0.03 | 0.008 | 0.008 | 0.06 | <0.008 | 0.03 | 0.25 | 0.5 | Wild type | Wild type |
| C. albicans | 42 | 0.5 | 1 | 8 | 4 | 0.008 | 0.06 | <0.008 | 0.03 | 0.25 | 0.5 | S645P | - |
MIC, minimum inhibitory concentration; AMB, amphotericin; AND, anidulafungin; CAS, caspofungin; MFG, micafungin; FCT, flucytosine; ITC, itraconazole; VRC, voriconazole, POS, Posaconazole; FLZ, fluconazole; ISA, isavuconazole. CLSI breakpoints [mg/L]: anidulafungin, caspofungin and micafungin S ≤ 0.25, R ≥ 1.